The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states.
about
Distinct patterns of the lipid alterations between genotype 1 and 2 chronic hepatitis C patients after viral clearanceLipase maturation factor 1 is required for endothelial lipase activity.Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatmentThe prevalence of metabolic syndrome and its predominant components among pre-and postmenopausal Ghanaian womenNew insights into the mechanism of low high-density lipoprotein cholesterol in obesityPrediction of metabolic syndrome among postmenopausal Ghanaian women using obesity and atherogenic markersFat depots, free fatty acids, and dyslipidemiaDyslipidemia in insulin resistance: clinical challenges and adipocentric therapeutic frontiers.Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome.Delayed clearance of triglyceride-rich lipoproteins in young, healthy obese subjectsCoronary heart disease in type 2 diabetes: mechanisms and comprehensive prevention strategies.Triglyceride Treatment in the Age of Cholesterol Reduction.Subcutaneous Adipocyte Lipolysis Contributes to Circulating Lipid Levels.Elevated cholesteryl ester transfer protein (CETP) activity, a major determinant of the atherogenic dyslipidemia, and atherosclerotic cardiovascular disease in South Asians.High-density lipoprotein cholesterol (HDL-C) in cardiovascular disease: effect of exercise training.Metabolic syndrome aggravates the increased endothelial activation and low-grade inflammation in subjects with familial low HDL.
P2860
Q34046758-C6D1E66B-C85E-42D3-8A8A-2C1039E2BAD3Q34955884-8C257EB9-BA31-44DE-B110-3FD593F0F7FBQ35029623-4EFB8BC0-F8F4-48CD-AEF2-276685DEF767Q35037381-F2120DF8-D3DA-4675-8C3C-625D690A0AF2Q35521069-EAADEC96-0F76-41BD-BCD6-89A8FF756D41Q36342333-32A4F1EB-A809-45F8-85C9-CEB29E540BB5Q36792405-15BAE8B5-968B-4A8E-93D6-61C52DF048E0Q37230403-D5910432-34DC-4747-9003-C3E42014BAB5Q37311118-E52179F3-47F6-491D-AD2C-4E03569104E4Q37418124-C3AB7BB5-DB3D-42A9-9B16-9F7C05194892Q38048842-EB19E782-2B5B-4F6A-975F-3C2C09685DD3Q38932760-CE178E31-9AD8-420B-BFC6-540B90929EB8Q41491014-D53F6692-B304-4BF7-A950-B74AA4BF6BBFQ44873060-B53FB881-1682-48C8-A10A-7D9004A5B953Q53499288-7198FF4A-0288-475C-8C76-DC4339064676Q53621412-5CB83878-09A6-49E4-BB99-6AAD78BCA90C
P2860
The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states.
@ast
The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states.
@en
The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states.
@nl
type
label
The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states.
@ast
The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states.
@en
The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states.
@nl
prefLabel
The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states.
@ast
The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states.
@en
The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states.
@nl
P2093
P1476
The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states.
@en
P2093
Gary F Lewis
Kristine D Uffelman
Shirya Rashid
P356
10.1016/S1056-8727(01)00191-X
P577
2002-01-01T00:00:00Z